Clinical Trial Update: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 pediatric MATCH trial evaluating ensartinib for patients with relapsed or refractory ALK- or ROS1-genomic altered advanced soli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Hepatoblastoma
• Langerhans Cell Histiocytosis
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Rhabdoid Tumor

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING